

US BANCORP \DE\
 Form 424B3
 December 20, 2001

Filed pursuant to Rule No. 424(b)(3)
 File Number 333-72626

PROSPECTUS SUPPLEMENT NO. 1
 (To Prospectus dated December 3, 2001)

\$1,483,179,000
 US BANCORP [Registered Trademark]
 Contingent Zero-Coupon Accreting Redeemable Securities(SM) (CZARS) (SM)
 (Convertible Senior Notes) Due 2021
 and
 Common Stock Issuable upon
 Conversion of the CZARS

This prospectus supplement supplements the prospectus dated December 3, 2001 of U.S. Bancorp relating to the sale by certain of our securityholders (including their pledgees, donees, assignees, transferees, successors and others who later hold any of the selling securityholders' interests) of up to \$1,483,179,000 aggregate principal amount at maturity of CZARS and the shares of common stock issuable upon conversion of the CZARS. You should read this prospectus supplement in conjunction with the prospectus, and this prospectus supplement is qualified by reference to the prospectus, except to the extent that the information in this prospectus supplement supersedes the information contained in the prospectus.

Investing in the CZARS or shares of common stock involves risks that are described in the "Risk Factors" section beginning on page 8 of the prospectus.

Neither the Securities and Exchange Commission, any state securities commission nor any other regulatory body has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is December 20, 2001.

The table of selling securityholders contained in the prospectus is hereby amended to add the entities who are named below as selling securityholders:

Name	Aggregate Principal Amount at Maturity of CZARS That May be Sold	Percentage of CZARS Outstanding	Number of Shares of Common Stock That May be Sold(1)
-----	-----	-----	-----
Deutsche Banc Alex Brown, Inc.	\$22,000,000	1.5%	531,146
Julius Baer Multibond Convertbond	\$1,500,000	*	36,214

Edgar Filing: US BANCORP \DE\ - Form 424B3

Additionally, the following contains updated information regarding the selling securityholders listed in the selling securityholder table in the prospectus:

Name	Aggregate Principal Amount at Maturity of CZARS That May be Sold	Percentage of CZARS Outstanding	Number of Shares of Common Stock That May be Sold(1)
-----	-----	-----	-----
Granville Capital Corporation	\$15,000,000	1.0%	362,145
Salomon Smith Barney Inc.	\$38,107,000	2.6%	920,017
All other holders of CZARS or future transferees, pledgees, donees, assignees or successors of any holders (3) (4)	\$168,570,000	11.4%	4,069,785
	-----	-----	-----

* Less than one percent (1%).

- (1) Assumes conversion of all of the holder's CZARS at a conversion rate of 24.1430 shares of common stock for every \$1,000 principal amount at maturity of the CZARS. This conversion rate is subject to adjustment as described under "Description of the CZARS-Conversion rights" in the attached prospectus. the number of shares of common stock issuable upon conversion of the CZARS may increase or decrease in the future.
- (2) Calculated based on Rule 13d-3(d)(1)(i) of the Exchange Act, using 1,969,001,279 shares of common stock outstanding as of September 30, 2001. In calculating this amount for each holder, we treated the number of shares of common stock issuable upon conversion of all of that holder's CZARS as if all of that holder's CZARS were converted. We do not assume conversion of any other holder's CZARS.
- (3) Information about other selling securityholders will be set forth in prospectus supplements.
- (4) Assumes that any other holders of CZARS, or any future pledgees, donees, assignees, transferees, or successors of or from any other holders of CZARS, do not beneficially own any shares of common stock in excess of the number of shares of common stock issuable upon conversion of the CZARS at the initial conversion rate.